MAAP Protein Enhances AAV Particle Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in rAAV vector manufacturing lies in understanding and controlling the cellular secretion of AAV particles and extracellular vesicles, which is crucial for gene therapy applications, as existing methods are inefficient and lack clarity on the mechanisms driving their egress from cells.
Innovation Solution
The discovery of a membrane-associated accessory protein (MAAP) derived from an alternate reading frame in the AAV genome, which promotes the formation and secretion of extracellular vesicles and AAV particles, providing a sequence for enhancing their secretion and association with these particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional rAAV vector manufacturing methods are used, then AAV particles can be produced, but the secretion efficiency and control over cellular egress remain poor
Solution Approach 1:
The patent introduces an extracellular vesicle (EV) as an intermediary carrier that mediates the secretion and delivery of AAV particles. The EV forms a composite structure with AAV particles, facilitating their controlled release from producer cells into the culture medium, thereby improving secretion efficiency while providing a regulated mechanism for cellular egress.
Solution Approach 2:
The patent creates a composite structure consisting of extracellular vesicles and AAV particles. This composite system combines the benefits of EV-mediated controlled secretion with the gene delivery capabilities of AAV, achieving both improved productivity and mechanistic control over the secretion process.
2Ease of operation
If AAV particles are secreted into cell culture media, then gene delivery capability is achieved, but the mechanism driving cellular secretion is unclear and variable
Solution Approach 1:
The patent establishes a feedback mechanism where the presence and composition of extracellular vesicles regulate the secretion process. By monitoring and controlling EV formation and association with AAV particles, the system provides consistent and reliable secretion efficiency across different production batches, resolving the variability issue.
3Productivity
If recombinant AAV serotypes are secreted in a pre-lytic manner, then some particles are released before cell lysis, but the efficiency varies significantly
Solution Approach 1:
The patent introduces dynamic control over the secretion process through the interaction between AAV particles and extracellular vesicles. The system can adapt between different secretion modes (pre-lytic, concurrent, or post-lytic) depending on the presence and characteristics of EVs, providing flexibility while maintaining high efficiency through the EV-mediated pathway.
Data Source
AI summary
Disclosed herein are compositions and methods for enhancing secretion of extracellular vesicles and/or AAV particles from cells. Disclosed herein are compositions and methods for altering and/or modifying the formation and/or secretion of extracellular vesicles and/or AAV particles from cells. Disclosed herein are compositions and methods for loading extracellular vesicles and or AAV particles with a cargo. Disclosed herein are isolated nucleic acid molecules encoding a polypeptide for promoting the formation of extracellular vesicles and AAV particles in cell or a polypeptide associated with extracellular vesicles and/or AAV particles secreted from a cell.